Bio Pharma Dive
NOVEMBER 9, 2021
Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday. The biotech is researching how to make medicines from transfer RNA molecules.
World of DTC Marketing
NOVEMBER 9, 2021
SUMMARY: Quantitative and qualitative data was gained through surveys with EPG Health’s multi-stakeholder databases (HCP, pharma, and service providers) and interviews conducted with pharma execs by Impatient Health. The objective was to identify new and preferred pathways for the creation and delivery of medical information. Key Findings 1 : HCPS ARE IN CONTROL AND PHARMA KNOWS IT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
NOVEMBER 11, 2021
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
JAMA Internal Medicine
NOVEMBER 7, 2021
This cross-sectional study of individuals from the French CONSTANCES cohort assesses whether the belief in having been infected with SARS-CoV-2, having serological test–confirmed COVID-19 infection, or both are associated with persistent physical symptoms often attributed to long COVID in the general adult population.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
NOVEMBER 12, 2021
The industry giant and mainstay of corporate America will separate its consumer health business from its drug and medical device units, which will retain the J&J brand.
World of DTC Marketing
NOVEMBER 12, 2021
SUMMARY: Today, more physicians and patients rely on the Internet to answer their questions about emerging treatments, including prescription drugs. If there is one industry that needs to think more about digital, it’s pharma. The reliance on agencies still is a building block, but who on the brand team is the person to ensure you maximize your digital strategy?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 12, 2021
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The MOATAI-VIR algorithm, developed by scientists at Emory University and Georgia Tech, was put through its paces in a study that showed it was able to predict 24 out of 26 clinical manifestations of COVID-19, including acute respiratory distress, blood clotting issues, cytokine storms, brain fog, and loss of sm
Bio Pharma Dive
NOVEMBER 8, 2021
Study results for Mirati's drug combined with Keytruda have been much anticipated, as the San Diego biotech aims to challenge Amgen and its rival KRAS-blocking drug Lumakras.
Pharma Mirror
NOVEMBER 10, 2021
Milan, CPhI Worldwide – hosted in-person at Fiera Milano, Italy (9-11 November, 2021) – opens its doors to international pharma for the first time in two years asindustry confidence surges to record highs according to executives in the CPhI Annual Survey. The survey insights are published as part of the CPhI Annual Report – which is launched each year at CPhI Worldwide – and compile the thoughts of over 370 executives from more than 30 countries.
Pharma Times
NOVEMBER 9, 2021
iiCON’s lead partner LSTM will independently validate CN Bio’s novel lung and lung-liver models
BioSpace
NOVEMBER 9, 2021
A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.
Bio Pharma Dive
NOVEMBER 11, 2021
Data presented at an Alzheimer's meeting raised more questions about the seeming benefit of Roche and AC Immune's drug semorinemab, which they claim is the first of its kind to slow deterioration of memory.
Pharma Mirror
NOVEMBER 10, 2021
Milan, Ahead of the world’s largest pharma event – CPhI Worldwide taking place in Milan, Italy (9-11 November, 2021) – the third part of the CPhI Annual Report is released with key findings for biologics manufacturing, biotechs and CDMOs. CPhI experts – Dawn Ecker, Managing Director of bioTRAK Database Services at BDO and Fiona Barry, Editor at GlobalData PharmSource – look ahead to 2025 to predict the future demand for biologicals by volume, as well as the total capacity available and, the cons
Pharma Times
NOVEMBER 9, 2021
Funding proceeds will be used to support ongoing trials of Gyroscopes investigational gene therapy GT005
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
NOVEMBER 8, 2021
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
Bio Pharma Dive
NOVEMBER 12, 2021
Detailed results presented Thursday show no difference between the biotech's drug and placebo on the study's main measures. But a seeming benefit in a subgroup of patients convinced the company to plan another trial.
BioPharma Reporter
NOVEMBER 9, 2021
Dutch stem cell company Neuroplast has announced positive Phase 1 results for its Neuro-Cells investigational stem cell treatment in patients suffering from Traumatic Spinal Cord Injury (TSCI).
Pharma Times
NOVEMBER 12, 2021
Researchers have said that next generation vaccines for COVID-19 should aim to induce a response against ‘replication proteins’
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 8, 2021
The UK government has announced £248 million in spending over the next year for a project to make it easier for patient test results and scans to be shared between hospitals, labs and GP surgeries. The aim is to “digitise diagnostics care” across the NHS, reducing the time it takes to diagnose health problems and get treatment started earlier, helping to address the massive backlog in care caused by the pandemic, according to a Department of Health and Social Care (DHSC) statement.
Bio Pharma Dive
NOVEMBER 11, 2021
The biotech claimed its NIH partners were involved only after a key discovery was made "by Moderna scientists using Moderna technology." The dispute could end up in court.
BioSpace
NOVEMBER 7, 2021
Researchers aren’t sure why the mRNA vaccines appear to, in rare cases, cause heart inflammation. The FDA said the risk appears higher within seven days of the second jab of the vaccines.
Pharma Times
NOVEMBER 12, 2021
The draft guidance has been published following an evaluation of new evidence on the use of the treatment
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
NOVEMBER 9, 2021
Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the first country in the world to approve the routine use of the therapy in this setting. The Scottish Medicines Consortium (SMC) has approved Tagrisso (osimertinib) for use within NHS Scotland as a monotherapy for adjuvant treatment after tumour removal in adult patients with stage IB-IIIA NSCLC whose tumours have epidermal growth factor (EGF
Bio Pharma Dive
NOVEMBER 8, 2021
The investment in CAR-T maker Autolus Therapeutics adds to a string of biotech deals the private equity firm has made since 2018.
XTalks
NOVEMBER 10, 2021
As big food brands shift towards ecommerce and direct-to-consumer (DTC) sales, there has been a notable uptick in their efforts to gain access to first-party consumer data. Whether it’s through personalized offerings or limited-edition products, many big food brands are employing marketing tactics to gain valuable data from consumers. First and foremost, the tactics are used to sell product — and clearly, they are working.
Pharma Times
NOVEMBER 11, 2021
Decision follows the UK government’s termination of their deal with Valneva in September
pharmaphorum
NOVEMBER 8, 2021
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The results suggest that the REGEN-COV (casirivimab/imdevimab) antibody could play a key role in protecting people who do not mount a sufficiently strong immune response after COVID-19 vaccines, according to the company.
Bio Pharma Dive
NOVEMBER 8, 2021
Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.
Scienmag
NOVEMBER 12, 2021
Carbon is the building block of all known life on our planet. The carbon cycle regulates the release and absorption of carbon from a number of natural sources — including the ocean, soil, geochemical processes, and human emissions — to maintain a delicate balance of this crucial element in our world. Credit: Kristin Rose Jutras […].
Pharma Times
NOVEMBER 11, 2021
Olumiant maintained a consistent safety profile in a long-term analysis of patients with rheumatoid arthritis
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
359 
Let's personalize your content